Other
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss
Vertex Pharmaceuticals Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss decreased by 15.2% to $8.40M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 10.5%, from $7.60M to $8.40M. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionOther
CategoryRisk
SignalLower is better
VolatilityStable
First reportedQ1 2024
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase indicates that a significant portion of the portfolio is suffering from prolonged valuation declines, raising concerns about potential future write-downs.
Detailed definition
The cumulative amount of unrealized losses for debt securities that have been in a continuous loss position for 12 month...
Peer comparison
Standard disclosure for insurance companies to track the aging of unrealized losses.
Metric ID:
other_debt_securities_available_for_sale_continuous_unre_23ad4cHistorical Data
7 periods
| Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|
| Value | $400.00K | $382.40M | $68.60M | $7.60M | $6.20M | $9.90M | $8.40M |
| QoQ Change | — | >999% | -82.1% | -88.9% | -18.4% | +59.7% | -15.2% |
| YoY Change | — | — | — | >999% | -98.4% | -85.6% | +10.5% |
Range$400.00K – $382.40M
CAGR+661.2%
Avg YoY Growth+406.6%
Median YoY Growth-37.5%
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, accumulated loss?
- Vertex Pharmaceuticals (VRTX) reported debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, accumulated loss of $8.40M in Q1 2026.
- How has Vertex Pharmaceuticals's debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, accumulated loss changed year-over-year?
- Vertex Pharmaceuticals's debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, accumulated loss increased by 10.5% year-over-year, from $7.60M to $8.40M.
- What does debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, accumulated loss mean?
- The total dollar amount of paper losses on debt securities that have been losing value for at least a year.